The use of HIV-1 integrase inhibitors in antiretroviral naive patients

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 409-414

  Lennox, Jeffrey L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1; integrase inhibitor; treatment naive

Indexed keywords

ATAZANAVIR; COBICISTAT; CREATININE; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; INTEGRASE; LIPID; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; BODY COMPOSITION; BODY FAT; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESISTANCE; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; GENE DOSAGE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; IC 50; LIPID COMPOSITION; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; COINFECTION; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; PYRROLIDINONES; QUINOLONES; TREATMENT OUTCOME;

EID: 84865652147     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283562a27     Document Type: Review

References (28)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guideline S for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services 2012. http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. [Accessed March 2012].
2. Guidelines version 6. European AIDS Clinical Society 2011. http://www. europeanaidsclinicalsociety.org/index.php?optioncom-content&view article&id59&Itemid41. [Accessed December 2011].
3. The DAD Study Group. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med 2007; 356:1723-1735.
4. Gandhi RT, Sax PE, Grinspoon SK. Metabolic and cardiovascular complications in HIV-infected patients: New challenges for a new age. J Infect Dis 2012; 205 (suppl 3): S353-S354.
5. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 Integrase Inhibitor Raltegravir (MK-0518) in Treatment Experienced Patients with Multidrug Resistant Virus: A Phase II Randomized Controlled Trial. Lancet 2007; 369:1261-1269.
6. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. N Engl J Med 2008; 359:339-354.
7. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained Antiretroviral Effect of Raltegravir after 96 Weeks of Combination Therapy in Treatment-Naíve Patients with HIV-1 Infection. J Acquir Immune Defic Syndr 2009; 52:350-356.
8. Lennox JL, DeJesus E, Lazzarin A, et al. Safety And Efficacy of Raltegravirbased Versus Efavirenz-based Combination Therapy in Treatment-Naíve Patients with HIV-1 Infection: A Multicenter, Double-Blind Randomized Controlled Trial. Lancet 2009; 374:796-806.
9. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus Efavirenz Regimens in Treatment-Naíve HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. J Acquir Immune Defic Syndr 2010; 55:39-48.
10. Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment- Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRK. Clin Infect Dis 2011; 53:807-816. This study demonstrates the long-term antiretroviral activity of raltegravir. Raltegravir was not only virologically noninferior to efavirenz, but was also bettertolerated. Lipid abnormalities were less common in patients receiving raltegravir. Patients in the raltegravir arm also gained less total body fat over 3 years.
11. DeJesus E, Rockstroh JK, Lennox JL, et al. Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naíve Patients: 192 Week Results from STARTMRK [Abstract 405]. In: IDSA 49th Annual Meeting. Boston; 20-23 October, 2011.
12. Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA. Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes. Curr HIV Res 2011; 9:174-179.
13. Rockstroh JK, Teppler H, Zhao J, et al. Clinical Efficacy of Raltegravir against B and Non-B Subtype HIV-1 in Phase III Clinical Studies. AIDS 2011; 25:1365-1369.
14. Eron JJ JrRockstroh K Jr Reynes J et al. RaltegravirOnce Daily or Twice Daily in Previously Untreated Patients with HIV-1 a Randomized Active Controlled Phase 3 Noninferiority Trial. Lancet Infect Dis 2011; 11907-915. In this study once daily raltegravir took longer than twice-daily raltegravir to produce virologic suppression was more likely to result in virologic failure.Despite this 83.2% of participants in the once daily group achieve virologic suppression. This may be a treatment option for patients with a low viral load A T-cell Count More Than 200 Cellsmlif No Other First-line Options Are Available.
15. Croce F, Vitello P, Dalla Pria A, et al. Severe Raltegravir Associated Rhabdomyolysis: A Case Report and Review of the Literature. Int J STD AIDS 2010; 21:783-785.
16. Koelsch KK, Boesecke C, McBride K, et al. Impact of treatment with Raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV Viral Reservoir. AIDS 2011; 25:2069-2078.
17. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011; 25:2113-2122. Once daily darunavir, when given with twice daily ritonavir, did not produce adequate virologic suppression.
18. Jackson A, Watson V, Back D, et al. Plasma and intracellular Pharmacokinetics of Darunavir/Ritonavir once daily and Raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr 2011; 58:450-457.
19. Goldwirt L, Braun Jp, de Castro N, et al. Switch from Enfuvirtide to Raltegravir lowers plasma concentrations of Darunavir and Tipranavir: A Pharmacokinetic substudy of the EASIER-ANRS 138 Trial. Antimicrob Agents Chemother 2011; 55:3613-3615.
20. Cattaneo D, Gervasoni C, Cozzi V, et al. Co-administration of Raltegravir Reduces Daily Darunavir Exposure in HIV-1 Infected patients. Pharmacol Res 2012; 65:198-203.
21. Reynes J, Lawal A, Pulido F, et al. Of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: The PROGRESS Study, 48-Week Results. HIV Clin Trials 2011; 12:255-267.
22. Cohen C, Elion R, Ruane P, et al. Randomized, Phase 2 Evaluation of Two Single Tablet Regimens Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for the initial treatment of HIV infection. AIDS 2011; 25:F7-F12. In this small trial the fixed-dose combination that contained elvitegravir appeared equivalent to a fixed-dose combination containing efavirenz. The elvitegravir containing combination was also better tolerated. These results indicated that the 'Quad' pill had sufficient antiviral activity to move forward into larger clinical trials.
23. Sax P, DeJesus E, Mills A, et al. Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir (Quad) Has Noninferior Efficacy and Favorable Safety Compared to Efavirenz/Emtricitabine/Tenofovir in Treatment-Naíve HIV-1 Subjects [Abstract 101]. In: 19th Conference on Retroviruses and Opportunistic Infections. Seattle; 5-8 March, 2012.
24. DeJesus E, Rockstroh J, Henry K, et al. Week 48 Results of an Ongoing Global Phase 3 Study Comparing Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate with Atazanavir/Ritonavir Boosted Plus Emtricitabine/ Tenofovir Disoproxil Fumarate in Treatment Naíve HIV-1 Subjects Showing Efficacy, Safety, and Pharmacokinetics [Abstract 627]. In: 19th Conference on Retroviruses and Opportunistic Infections. Seattle; 5-8 March, 2012.
25. Song I, Borland J, Chen S, et al. Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir. Antimicrob Agents Chemother 2012; 56:1627-1629.
26. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. J Infect Dis 2011; 204:1811-1815.
27. Min S, Sloan L, DeJesus E, et al. Antiviral Activity, Safety, and Pharmacokinetics/ Pharmacodynamics of Dolutegravir as 10 day monotherapy in HIV-1- infected adults. AIDS 2011; 25:1737-1745. In this dose ranging study, a 50 mg dose of dolutegravir given as monotherapy reduced viral load by greater than 1.5 log10. This result was achieved without any pharmacologic booster, and with once daily dosing of the dolutegravir. Lower doses of the dolutegravir were less effective, so the 50 mg dose moved forwardinto phase 2 clinical trials.
28. van Lunzen J, Maggiolo F, Arribas JR, et al. Once Daily Dolutegravir (S/GSK 134-9572) in Combination Therapy in Antiretroviral-Naíve Adults with HIV: Planned Interim 48 Week Results from Spring-One, a Dose Ranging, Randomized, Phase 2b Trial. Lancet Infect Dis 2012; 12:111-118.